Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells

Oncotarget

Volumn 6, Issue 1, 2015, Pages 221-223

  Petti, Consalvo ^a   Picco, Gabriele ^a,b   Martelli, Maria Luisa ^a   Trisolini, Elena ^b,c   Bucci, Enrico ^d   Perera, Timothy ^e   Isella, Claudio ^a,b   Medico, Enzo ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^d BioDigitalValley Srl   (Italy)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

BRAF; Drug resistance; Gastric cancer; MET; RAF1

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; B RAF KINASE; CETUXIMAB; COMPLEMENTARY DNA; JNJ 38877605; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAF1 PROTEIN; RETROVIRUS VECTOR; SCATTER FACTOR RECEPTOR; SELUMETINIB; UNCLASSIFIED DRUG; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; BRAF PROTEIN, HUMAN; BRAF PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SULFONE;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; GASTRIC CANCER CELL LINE; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MET GENE; MOUSE; NONHUMAN; STOMACH CANCER; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE LIBRARY; HUMAN; METABOLISM; NUDE MOUSE; PHENOTYPE; STOMACH TUMOR; TIME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; RAF KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; SULFONES; TIME FACTORS;

EID: 84921390342     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2771     Document Type: Article

References (47)

1. Lemmon MA and Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-1134.
2. Sharma SV and Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes & development. 2007; 21(24):3214-3231.
3. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol. 2010; 21 Suppl 7:vii36-40.
4. Vecchione L, Jacobs B, Normanno N, Ciardiello F and Tejpar S. EGFR-targeted therapy. Exp Cell Res. 2011; 317(19):2765-2771.
5. Blumenschein GR, Mills GB and Gonzalez-Angulo AM. Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy. J Clin Oncol. 2012; 30(26):3287-96.
6. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT and Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002; 13(1):41-59.
7. Christensen JG, Burrows J and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005; 225(1):1-26.
8. Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y and Kusunoki M. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 2012; 40(2):583-591.
9. Avan A, Maftouh M, Funel N, Ghayour-Mobarhan M, Boggi U, Peters GJ and Giovannetti E. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside. Curr Med Chem. 2014; 21(8):975-989.
10. Scagliotti GV, Novello S and von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013; 39(7):793-801.
11. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ and Kim WH. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012; 107(2):325-333.
12. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J and Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006; 103(7):2316-2321.
13. Sergina NV and Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007; 13(12):527-534.
14. Engelman JA and Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008; 18(1):73-79.
15. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM and Johns TG. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia. 2009; 11(5):448-458, 442 p following 458.
16. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486(7404):532-536.
17. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T and Kumagai H. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003; 31(11):1007-1014.
18. Ponzetto C, Giordano S, Peverali F, Della Valle G, Abate ML, Vaula G and Comoglio PM. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene. 1991; 6(4):553-559.
19. Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, Srinivasa SP, Zhao Y, Aparicio S, Rejto PA, Christensen JG and Ching KA. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation. PLoS One. 2012; 7(6):e39653.
20. Simonsen H and Lodish HF. Cloning by function: expression cloning in mammalian cells. Trends Pharmacol Sci. 1994; 15(12):437-441.
21. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM and Mendel DB. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003; 63(21):7345-7355.
22. Martelli ML, Isella C, Mira A, Fu L, Cantarella D and Medico E. Exploiting orthologue diversity for systematic detection of gain-of-function phenotypes. BMC Genomics. 2008; 9:254.
23. Mira A, Isella C, Renzulli T, Cantarella D, Martelli ML and Medico E. The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer. Oncogene. 2009; 28(50):4444-4455.
24. Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009; 15(22):6841-6851.
25. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480(7377):387-390.
26. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM and Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 2010; 70(19):7580-7590.
27. Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy DA, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M, McCarthy C, Sellers WR, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res. 2011; 71(15):5255-5264.
28. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM and Giordano S. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 2010; 9:121.
29. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM and Trusolino L. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal. 2009; 2(100):ra80.
30. Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K and Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68(21):8673-8677.
31. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K and Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 2009; 28(20):2119-2123.
32. Jeuken JW and Wesseling P. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol. 2010; 222(4):324-328.
33. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, Broniscer A, Young BD, Ellison DW, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009; 218(2):172-181.
34. Lawson AR, Tatevossian RG, Phipps KP, Picker SR, Michalski A, Sheer D, Jacques TS and Forshew T. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol. 2010; 120(2):271-273.
35. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011; 121(6):763-774.
36. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH and Stephenson JR. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A. 1983; 80(14):4218-4222.
37. Garnett MJ, Rana S, Paterson H, Barford D and Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell. 2005; 20(6):963-969.
38. Fukui M, Yamamoto T, Kawai S, Mitsunobu F and Toyoshima K. Molecular cloning and characterization of an activated human c-raf-1 gene. Mol Cell Biol. 1987; 7(5):1776-1781.
39. Mölders H, Defesche J, Müller D, Bonner TI, Rapp UR and Müller R. Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion. EMBO J. 1985; 4(3):693-698.
40. Stanton VP and Cooper GM. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol. 1987; 7(3):1171-1179.
41. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010; 16(7):793-798.
42. Cornelis S, Bruynooghe Y, Van Loo G, Saelens X, Vandenabeele P and Beyaert R. Apoptosis of hematopoietic cells induced by growth factor withdrawal is associated with caspase-9 mediated cleavage of Raf-1. Oncogene. 2005; 24(9):1552-1562.
43. Santarpia L, Lippman SM and El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):103-119.
44. Niault TS and Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010; 31(7):1165-1174.
45. Rushworth LK, Hindley AD, O'Neill E and Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol. 2006; 26(6):2262-2272.
46. Poulikakos PI, Zhang C, Bollag G, Shokat KM and Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464(7287):427-430.
47. Follenzi A, Sabatino G, Lombardo A, Boccaccio C and Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther. 2002; 13(2):243-260.